<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2020.96036</article-id><article-id pub-id-type="publisher-id">PI-38725</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20200600000_19331875.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  越鞠丸治疗抑郁症较传统西药治疗优越性Meta分析
  Meta-Analysis on the Superiority of Yueju Pill over Traditional Western Medicine in Treating Depression
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>付</surname><given-names>裕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>冬梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>木</surname><given-names>本荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>国</surname><given-names>锦琳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>成都中医药大学，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>09</volume><issue>06</issue><fpage>243</fpage><lpage>252</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：系统研究中药越鞠丸治疗抑郁症较西药治疗抑郁症的优越性。方法：在中国知网、万方、维普、PubMed、Europe PMC数据库中检索以越鞠丸治疗抑郁症为基础的文献，并将越鞠丸治疗不同的抑郁症进行分类。先提取各小组纳入文献的数据并进行质量评价，使用Review Manager 5.3软件进行Meta分析，主要结局为治疗有效率，次要结局为HAMD (汉密顿抑郁量表)。再观察各分类小组的异同，以期对纳入的文献进行科学性评价。结果：共纳入13篇文献进行研究，包含1091例抑郁症患者。治疗组以越鞠丸为基础方组总计582例，对照组为传统西药治疗组总计509例。根据Meta分析结果显示：以越鞠丸为基础方治疗原发性抑郁症患者有效率(RR = 1.14, 95% CI [1.00, 1.30], P = 0.06)；治疗脑卒中后抑郁症患者有效率(RR = 1.18, 95% CI [1.00, 1.40], P = 0.05)；治疗原发性抑郁症患者HAMD (SMD = 0.02, 95% CI [−0.27, 0.31], P = 0.89)；治疗脑卒中后抑郁症患者HAMD (SMD = −0.07, 95% CI [−0.30, 0.16], P = 0.53)。结论：以越鞠丸为基础方治疗各种抑郁症(以原发性抑郁和脑卒中后抑郁为例)较传统的西药治疗的效果更明显，且不良反应发生率优于传统西药治疗。 Objective: To systematically study the superiority of Yueju Pill in the treatment of depression com-pared with traditional western medicine. Methods: Literature based on the treatment of depression by Yueju Pill was searched in CNKI, WANFANG, VIP, PubMed and Europe PMC databases, and different types of depression were classified. First of all, the data from the included literature of each group were extracted for quality evaluation. Meta-analysis was conducted using Review Manager 5.3 software. The primary outcome was treatment efficiency, while the secondary outcome was HAMD. Then observe the similarities and differences of each classification group in order to make a scientific evaluation of the included literature. Results: A total of 13 articles were included in 1091 patients with depression. A total of 582 patients in the treatment group were treated with Yueju Pill, while 509 patients in the control group were treated with traditional western medicine. Meta-analysis results showed that: using Yueju Pill as the basis for the treatment of primary depression in patients, the efficiency was (R = 1.14, 95% CI [1.00, 1.30], P = 0.06), for the treatment of post-stroke depression (RR = 1.18, 95% CI [1.00, 1.40], P = 0.05), for the treatment of HAMD in pa-tients with primary depression (SMD = 0.02, 95% CI [−0.27, 0.31], P = 0.89), for the treatment of HAMD in patients with post-stroke depression (SMD = −0.07, 95% CI [−0.30, 0.16], P = 0.53). Conclusion: Yueju Pill is more effective in treating various kinds of depression (primary depression and post-stroke depression as examples) than traditional western medicine, and the incidence of adverse reactions is better than traditional western medicine. 
  
 
</p></abstract><kwd-group><kwd>越鞠丸，抑郁症，传统西药，Meta分析, Yueju Pill</kwd><kwd> Depression</kwd><kwd> Tradition Western Medicine</kwd><kwd> Meta-Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：系统研究中药越鞠丸治疗抑郁症较西药治疗抑郁症的优越性。方法：在中国知网、万方、维普、PubMed、Europe PMC数据库中检索以越鞠丸治疗抑郁症为基础的文献，并将越鞠丸治疗不同的抑郁症进行分类。先提取各小组纳入文献的数据并进行质量评价，使用Review Manager 5.3软件进行Meta分析，主要结局为治疗有效率，次要结局为HAMD (汉密顿抑郁量表)。再观察各分类小组的异同，以期对纳入的文献进行科学性评价。结果：共纳入13篇文献进行研究，包含1091例抑郁症患者。治疗组以越鞠丸为基础方组总计582例，对照组为传统西药治疗组总计509例。根据Meta分析结果显示：以越鞠丸为基础方治疗原发性抑郁症患者有效率(RR = 1.14, 95% CI [1.00, 1.30], P = 0.06)；治疗脑卒中后抑郁症患者有效率(RR = 1.18, 95% CI [1.00, 1.40], P = 0.05)；治疗原发性抑郁症患者HAMD (SMD = 0.02, 95% CI [−0.27, 0.31], P = 0.89)；治疗脑卒中后抑郁症患者HAMD (SMD = −0.07, 95% CI [−0.30, 0.16], P = 0.53)。结论：以越鞠丸为基础方治疗各种抑郁症(以原发性抑郁和脑卒中后抑郁为例)较传统的西药治疗的效果更明显，且不良反应发生率优于传统西药治疗。</p></sec><sec id="s2"><title>关键词</title><p>越鞠丸，抑郁症，传统西药，Meta分析</p></sec><sec id="s3"><title>Meta-Analysis on the Superiority of Yueju Pill over Traditional Western Medicine in Treating Depression<sup> </sup></title><p>Yu Fu<sup>*</sup>, Dongmei Wang<sup>*</sup>, Benrong Mu<sup>#</sup>, Jinlin Guo<sup>#</sup></p><p>Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan</p><p><img src="//html.hanspub.org/file/8-1710241x5_hanspub.png" /></p><p>Received: Nov. 5<sup>th</sup>, 2020; accepted: Nov. 17<sup>th</sup>, 2020; published: Nov. 24<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/8-1710241x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To systematically study the superiority of Yueju Pill in the treatment of depression compared with traditional western medicine. Methods: Literature based on the treatment of depression by Yueju Pill was searched in CNKI, WANFANG, VIP, PubMed and Europe PMC databases, and different types of depression were classified. First of all, the data from the included literature of each group were extracted for quality evaluation. Meta-analysis was conducted using Review Manager 5.3 software. The primary outcome was treatment efficiency, while the secondary outcome was HAMD. Then observe the similarities and differences of each classification group in order to make a scientific evaluation of the included literature. Results: A total of 13 articles were included in 1091 patients with depression. A total of 582 patients in the treatment group were treated with Yueju Pill, while 509 patients in the control group were treated with traditional western medicine. Meta-analysis results showed that: using Yueju Pill as the basis for the treatment of primary depression in patients, the efficiency was (R = 1.14, 95% CI [1.00, 1.30], P = 0.06), for the treatment of post-stroke depression (RR = 1.18, 95% CI [1.00, 1.40], P = 0.05), for the treatment of HAMD in patients with primary depression (SMD = 0.02, 95% CI [−0.27, 0.31], P = 0.89), for the treatment of HAMD in patients with post-stroke depression (SMD = −0.07, 95% CI [−0.30, 0.16], P = 0.53). Conclusion: Yueju Pill is more effective in treating various kinds of depression (primary depression and post-stroke depression as examples) than traditional western medicine, and the incidence of adverse reactions is better than traditional western medicine.</p><p>Keywords:Yueju Pill, Depression, Tradition Western Medicine, Meta-Analysis</p><disp-formula id="hanspub.38725-formula45"><graphic xlink:href="//html.hanspub.org/file/8-1710241x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-1710241x8_hanspub.png" /> <img src="//html.hanspub.org/file/8-1710241x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>根据世界卫生组织最新报告，到2020年抑郁症成为导致人类死亡或致残的第二大人类疾病 [<xref ref-type="bibr" rid="hanspub.38725-ref1">1</xref>]。对于抑郁症患者的治疗，现代临床常采用的传统西药治疗有很大的副作用，常见不良反应有头痛、恶心、呕吐、失眠、视物模糊、肝功能轻度异常 [<xref ref-type="bibr" rid="hanspub.38725-ref2">2</xref>]。基于已知的越鞠丸与西药对于抑郁症的治疗效果分析，对以越鞠丸为基础方治疗各种抑郁症相较传统西药治疗是否能够取得明显疗效的同时减少不良反应的发生率这一问题进行探讨。本此研究主要对越鞠丸与传统西药治疗抑郁症效果随机对照试验进行系统性分析评价，用以探讨哪种用药方式对于治疗抑郁症更具有优越性，以期数据分析能够为临床治疗抑郁症提供参考。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 检索策略</title><p>在中文检索数据库：中国知网、万方数据知识服务平台、维普中文科技期刊数据库和英文检索数据库：PubMed、Europe PMC中以主题加关键词词组的形式进行检索。其中，中文检索词：越鞠丸、抑郁症、抑郁、产后抑郁、卒中后抑郁、中风后抑郁、更年期抑郁。英文检索词：Yueju Pill、Yueju、depressive disorder。检索年限均从2003年~2018年。检索词组合策略均采用主题词组合、关键词组合、摘要词组合、主题加关键词组合、主题加摘要词组合和全文篇组合6种组合形式。</p></sec><sec id="s6_2"><title>2.2. 选择标准</title><sec id="s6_2_1"><title>2.2.1. 纳入标准</title><p>1) 研究类型：2003年~2018年国内外医学期刊公开发表的与越鞠丸治疗有关的各种抑郁症的文献，采用随机对照试验；2) 研究对象：抑郁症患者；3) 干预措施：治疗组以越鞠丸为基础方，对照组不含越鞠丸；4) 提供了具有特异性的研究指标：痊愈、有效、显效、无效、总有效率、不良反应、HAMD评分；5) 是否设置有以越鞠丸为基础方治疗各种抑郁症和传统西药治疗抑郁症的对照试验，详情见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic inclusion of documentation informatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >研究</th><th align="center" valign="middle" >样本量(T/C)</th><th align="center" valign="middle" >性别 (M/F)</th><th align="center" valign="middle" >分期</th><th align="center" valign="middle" >治疗组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >结局指标</th></tr></thead><tr><td align="center" valign="middle" >潘洪峰2008 [<xref ref-type="bibr" rid="hanspub.38725-ref5">5</xref>]</td><td align="center" valign="middle" >13/11</td><td align="center" valign="middle" >9/15</td><td align="center" valign="middle" >4周I期</td><td align="center" valign="middle" >口服越鞠保和丸水丸剂</td><td align="center" valign="middle" >口服百忧解</td><td align="center" valign="middle" >②④⑤⑥⑦</td></tr><tr><td align="center" valign="middle" >李蓉2014 [<xref ref-type="bibr" rid="hanspub.38725-ref6">6</xref>]</td><td align="center" valign="middle" >36/31</td><td align="center" valign="middle" >29/38</td><td align="center" valign="middle" >4周I期，共II期</td><td align="center" valign="middle" >越鞠丸加味治疗</td><td align="center" valign="middle" >多虑平治疗</td><td align="center" valign="middle" >①②③④⑥⑦</td></tr><tr><td align="center" valign="middle" >李仲平2010 [<xref ref-type="bibr" rid="hanspub.38725-ref7">7</xref>]</td><td align="center" valign="middle" >35/34</td><td align="center" valign="middle" >22/47</td><td align="center" valign="middle" >6周</td><td align="center" valign="middle" >越鞠升降汤治疗</td><td align="center" valign="middle" >盐酸氟西汀胶囊治疗</td><td align="center" valign="middle" >①③④⑤⑥⑦</td></tr><tr><td align="center" valign="middle" >王少华2001 [<xref ref-type="bibr" rid="hanspub.38725-ref8">8</xref>]</td><td align="center" valign="middle" >56/26</td><td align="center" valign="middle" >17/65</td><td align="center" valign="middle" >随访3个月</td><td align="center" valign="middle" >越鞠丸</td><td align="center" valign="middle" >谷维素</td><td align="center" valign="middle" >①②④</td></tr><tr><td align="center" valign="middle" >张煜萱2018 [<xref ref-type="bibr" rid="hanspub.38725-ref9">9</xref>]</td><td align="center" valign="middle" >10/10</td><td align="center" valign="middle" >5/15</td><td align="center" valign="middle" >28天</td><td align="center" valign="middle" >越鞠丸 + 常规治疗</td><td align="center" valign="middle" >常规治疗</td><td align="center" valign="middle" >①②③⑦</td></tr><tr><td align="center" valign="middle" >叶实现2006 [<xref ref-type="bibr" rid="hanspub.38725-ref10">10</xref>]</td><td align="center" valign="middle" >31/30</td><td align="center" valign="middle" >28/33</td><td align="center" valign="middle" >30天</td><td align="center" valign="middle" >越鞠丸加味</td><td align="center" valign="middle" >抑郁为主服优克， 焦虑为主服阿普唑仑</td><td align="center" valign="middle" >①②③④⑤⑥⑦</td></tr><tr><td align="center" valign="middle" >成金汉2009 [<xref ref-type="bibr" rid="hanspub.38725-ref11">11</xref>]</td><td align="center" valign="middle" >32/32</td><td align="center" valign="middle" >34/30</td><td align="center" valign="middle" >30天I期，共III期</td><td align="center" valign="middle" >康复锻炼 + 越鞠丸汤剂</td><td align="center" valign="middle" >康复锻炼 + 百忧解</td><td align="center" valign="middle" >①③④⑤</td></tr><tr><td align="center" valign="middle" >李淑芬2011 [<xref ref-type="bibr" rid="hanspub.38725-ref12">12</xref>]</td><td align="center" valign="middle" >46/39</td><td align="center" valign="middle" >35/50</td><td align="center" valign="middle" >6周</td><td align="center" valign="middle" >常规治疗 + 康复训练 + 越鞠丸加味治疗</td><td align="center" valign="middle" >常规治疗 + 康复训练 + 多塞平片</td><td align="center" valign="middle" >①③④⑤⑥⑦</td></tr><tr><td align="center" valign="middle" >孙占卫2014 [<xref ref-type="bibr" rid="hanspub.38725-ref13">13</xref>]</td><td align="center" valign="middle" >54/42</td><td align="center" valign="middle" >38/58</td><td align="center" valign="middle" >49天</td><td align="center" valign="middle" >康复训练 + 越鞠丸</td><td align="center" valign="middle" >康复训练 + 多塞平片</td><td align="center" valign="middle" >①②④⑤⑦</td></tr><tr><td align="center" valign="middle" >王琪2007 [<xref ref-type="bibr" rid="hanspub.38725-ref14">14</xref>]</td><td align="center" valign="middle" >45/45</td><td align="center" valign="middle" >29/61</td><td align="center" valign="middle" >8周</td><td align="center" valign="middle" >常规治疗 + 康复训练 + 朱丹溪越鞠丸</td><td align="center" valign="middle" >常规治疗 + 康复训练 + 氟西汀胶囊</td><td align="center" valign="middle" >①②③④⑤⑦</td></tr><tr><td align="center" valign="middle" >刘斯尧2014 [<xref ref-type="bibr" rid="hanspub.38725-ref15">15</xref>]</td><td align="center" valign="middle" >26/26</td><td align="center" valign="middle" >25/27</td><td align="center" valign="middle" >2个月</td><td align="center" valign="middle" >常规治疗 + 康复训练 + 柴胡越鞠丸加减</td><td align="center" valign="middle" >常规治疗 + 康复训练</td><td align="center" valign="middle" >⑦</td></tr><tr><td align="center" valign="middle" >李宝玲2003 [<xref ref-type="bibr" rid="hanspub.38725-ref16">16</xref>]</td><td align="center" valign="middle" >35/25</td><td align="center" valign="middle" >27/33</td><td align="center" valign="middle" >30天</td><td align="center" valign="middle" >越鞠丸加减</td><td align="center" valign="middle" >阿斯匹林 + 多虑平</td><td align="center" valign="middle" >①②③④⑤⑦</td></tr><tr><td align="center" valign="middle" >李建国2009 [<xref ref-type="bibr" rid="hanspub.38725-ref17">17</xref>]</td><td align="center" valign="middle" >163/158</td><td align="center" valign="middle" >180/141</td><td align="center" valign="middle" >4周</td><td align="center" valign="middle" >脑血管病常规治疗 + 越鞠丸</td><td align="center" valign="middle" >脑血管病常规治疗</td><td align="center" valign="middle" >②④</td></tr></tbody></table></table-wrap><p>表1. 各纳入文献的基本资料</p><p>注：T：治疗组；C：对照组；M：男性；F：女性；①：痊愈；②：有效；③：显效；④：无效；⑤：总有效率；⑥：不良反应；⑦：HAMD评分。</p></sec><sec id="s6_2_2"><title>2.2.2. 排除标准</title><p>1) 重复发表文献；2) 文献数据与研究内容不相关；3) 不同文献中出现同一试验进行说明；4) 试验设计不符合随机对照原则；5) 试验对象不合要求；6) 没有提供可研究的特异性指标；7) 没有单独以某个抑郁症患者作为研究对象。</p></sec><sec id="s6_2_3"><title>2.2.3. 结局指标</title><p>1) 有效率 = (痊愈 + 有效 + 显效)/该组总人数；2) HAMD：汉密顿抑郁量表(HAMD) [<xref ref-type="bibr" rid="hanspub.38725-ref3">3</xref>] 24项版本总分 ≥ 20分；3) 不良反应：头痛恶心、口渴便秘、食欲下降、困倦乏力、记忆力下降、视物模糊、肝功能异常。</p></sec></sec><sec id="s6_3"><title>2.3. 文献质量评价方法</title><sec id="s6_3_1"><title>2.3.1. 资料提取</title><p>由两名研究者单独提取，进行核对商讨。如遇分歧，与其他研究者共同讨论解决。提取数据主要有：1) 资料来源(知网、万方、维普、PubMed、Europe PMC)；2) 研究课题、第一作者、发表年份及发表期刊；3) 方法学质量评价标准；4) 治疗组、对照组的研究对象、数据是否完整、患者患病情况；5) 是否含有特异性指标。</p></sec><sec id="s6_3_2"><title>2.3.2. 方法质量学评估</title><p>由两名研究者各自采用Rewman5.3软件中的偏倚风险评估工具对最终纳入研究的文献，根据改良后Jadad评分方法进行评价，1~3分为低质量，4~7分为高质量 [<xref ref-type="bibr" rid="hanspub.38725-ref4">4</xref>]。评价内容：1) 随机分配：充分、不清楚、不充分；2) 分配隐藏：充分、不清楚、不充分；3) 盲法：正确、不清楚、不正确；4) 结果数据的完整性：完整、不清楚、不完整；5) 选择性报告结果：无、有、未提；6) 其他偏移：无、不清楚、有等方面。评价过程中，遇到分歧则通过商讨决定，评价结果见表2。</p></sec></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>使用Cochrane协作网提供的Review manager 5.3软件包对数据进行Meta分析。计数资料：相对危险度(Relative risk, RR)表示效应量，计量资料：标准化均数差(STD mean difference, SMD)表示效应量，两者均以95%的置信区间(Confidence interval, CI)表示。纳入研究异质性检验结果P &gt; 0.1或I<sup>2</sup> ≤ 50%说明同质性好，采用固定效应模型进行Meta分析；异质性检验结果P ≤ 0.1或I<sup>2</sup> &gt; 50%说明数据存在异质性，采用随机效应模型进行Meta分析。同时使用Review Manager 5.3软件包对纳入研究的文献进行偏倚风险评价，得到偏倚风险百分图(Risk of bias graph)和偏倚风险总结图(Risk of bias summary)，结果见图1，图2。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 文献检索结果</title><p>根据研究课题初步检索相关文献168篇，利用NoteExpress3.2软件剔除重复文献103篇，通过阅读</p><p>图1. 偏倚风险百分图</p><p>图2. 偏倚风险总结图</p><p>文题和摘要删除不合格40篇，初步纳入25篇，阅读全文后删去试验重复、实验设计不符合随机对照原则、实验对象不合要求的文献共12篇，最终纳入13篇，结果见图3。</p></sec><sec id="s7_2"><title>3.2. 基础纳入文献分析</title><p>将纳入Meta分析的文献的基本资料进行分析总结并绘制成表，归纳内容包括样本量、研究对象性别、治疗周期、实验分组依据及合理的结局指标，结果见表1。</p></sec><sec id="s7_3"><title>3.3. 纳入文献质量评价</title><p>各纳入文献的质量评价如表2。</p><p>图3. 流程图</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Methodological quality assessment form of literature include</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >纳入研究</th><th align="center" valign="middle" >随机方法</th><th align="center" valign="middle" >分配隐藏</th><th align="center" valign="middle" >盲法</th><th align="center" valign="middle" >结果数据 是否完整</th><th align="center" valign="middle" >选择性 报告结果</th><th align="center" valign="middle" >其他偏移</th><th align="center" valign="middle" >Jadad评分</th></tr></thead><tr><td align="center" valign="middle" >潘洪峰2008 [<xref ref-type="bibr" rid="hanspub.38725-ref5">5</xref>]</td><td align="center" valign="middle" >开放式随机法分组</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >李蓉2014 [<xref ref-type="bibr" rid="hanspub.38725-ref6">6</xref>]</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >李仲平2010 [<xref ref-type="bibr" rid="hanspub.38725-ref7">7</xref>]</td><td align="center" valign="middle" >提及随机但无具体方法</td><td align="center" valign="middle" >双盲</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >王少华2001 [<xref ref-type="bibr" rid="hanspub.38725-ref8">8</xref>]</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >张煜萱2018 [<xref ref-type="bibr" rid="hanspub.38725-ref9">9</xref>]</td><td align="center" valign="middle" >按就诊顺序编号纳入分组</td><td align="center" valign="middle" >单盲</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >叶实现2006 [<xref ref-type="bibr" rid="hanspub.38725-ref10">10</xref>]</td><td align="center" valign="middle" >提及随机但无具体方法</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >成金汉2009 [<xref ref-type="bibr" rid="hanspub.38725-ref11">11</xref>]</td><td align="center" valign="middle" >随机数字表法分组</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >李淑芬2011 [<xref ref-type="bibr" rid="hanspub.38725-ref12">12</xref>]</td><td align="center" valign="middle" >按就诊顺序随机</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >孙占卫2014 [<xref ref-type="bibr" rid="hanspub.38725-ref13">13</xref>]</td><td align="center" valign="middle" >随机平行对照法</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >王琪2007 [<xref ref-type="bibr" rid="hanspub.38725-ref14">14</xref>]</td><td align="center" valign="middle" >提及随机但无具体方法</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >刘斯尧2014 [<xref ref-type="bibr" rid="hanspub.38725-ref15">15</xref>]</td><td align="center" valign="middle" >提及随机但无具体方法</td><td align="center" valign="middle" >双盲</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >李宝玲2003 [<xref ref-type="bibr" rid="hanspub.38725-ref16">16</xref>]</td><td align="center" valign="middle" >提及随机但无具体方法</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >李建国2009 [<xref ref-type="bibr" rid="hanspub.38725-ref17">17</xref>]</td><td align="center" valign="middle" >随机数字表法分组</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未提</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表2. 各纳入文献的质量评价</p></sec><sec id="s7_4"><title>3.4. Meta分析结果</title>联合越鞠丸治疗抑郁症对患者影响结果Meta分析<p>1) 原发性抑郁有效率：该项分析共纳入文献4篇 [<xref ref-type="bibr" rid="hanspub.38725-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref8">8</xref>]，共纳入242例。治疗组140例。对照组102例。异质性研究显示，P = 0.72，I<sup>2</sup> = 0%，各研究间差异无统计学异质性，故采用固定效应模型。Meta结果显示，治疗组有效率高于对照组，差异具有显著统计学意义。有效率(RR = 1.14, 95% CI [1.00, 1.30], P = 0.06)这说明了联合越鞠丸治疗原发性抑郁症相对于传统西药治疗原发性抑郁症效果更显著，结果见图4。</p><p>图4. 原发性抑郁有效率森林图</p><p>2) 脑卒中后抑郁有效率：该项分析共纳入文献6篇 [<xref ref-type="bibr" rid="hanspub.38725-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref17">17</xref>]，共包含704例，治疗组375例，对照组329例。异质性研究显示，P &lt; 0.0001，I<sup>2</sup> = 82%，各研究间差异存在统计学异质性，故采用随机效应模型。根据Meta分析结果显示，治疗组有效率高于对照组，差异具有显著统计学意义。脑卒中后抑郁有效率(RR = 1.18, 95% CI [1.00, 1.40], P = 0.05)这说明了以越鞠丸为基础方治疗脑卒中后抑郁症相对于传统西药治疗脑卒中后抑郁症效果更显著，结果见图5。</p><p>图5. 脑卒中后抑郁有效率森林图</p><p>3) 原发性抑郁HAMD评分：4项研究报告了HAMD评分 [<xref ref-type="bibr" rid="hanspub.38725-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref9">9</xref>]，共纳入180例，治疗组94例，对照组86例。异质性研究显示，P = 1.00，I<sup>2</sup> = 0%，各研究间差异无统计学异质性，故采用固定效应模型。根据Meta分析结果显示，治疗组HAMD评分优于对照组，差异具有显著统计学意义。原发性抑郁HAMD (SMD = 0.02, 95% CI [−0.27, 0.31], P = 0.89)这说明了以越鞠丸为基础方治疗原发性抑郁症相对于传统西药治疗原发性抑郁症HAMD评分普遍更低，结果见图6。</p><p>4) 脑卒中后抑郁HAMD评分：4项研究报告了HAMD评分 [<xref ref-type="bibr" rid="hanspub.38725-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38725-ref16">16</xref>]，共纳入298例，治疗组160例，对照组138例。异质性研究显示，P = 0.97，I<sup>2</sup> = 0%，各研究间差异无统计学异质性，故采用固定效应模型。根据Meta分析结果显示，治疗组HAMD评分优于对照组，差异具有显著意义。脑卒中后抑郁HAMD (SMD = −0.07, 95% CI [−0.30, 0.16], P = 0.53)这说明了以越鞠丸为基础方治疗脑卒中后抑郁症相对于传统西药治疗脑卒中后抑郁症HAMD评分普遍更低，结果见图7。</p><p>图6. 原发性抑郁HAMD评分森林图</p><p>图7. 卒中后抑郁HAMD评分森林图</p></sec><sec id="s7_5"><title>3.5. 发表偏倚</title><p>漏斗图对发表偏倚判断结果的稳定性受纳入研究数量的影响，当纳入研究较少时，其结果往往不够稳定。根据有效率的研究数据绘制的漏斗图，结果见图8。可知漏斗图明显不对称，提示纳入的4篇文献存在一定程度的发表偏倚。</p><p>图8. 原发性抑郁有效率漏斗图</p></sec></sec><sec id="s8"><title>4. 讨论</title><sec id="s8_1"><title>4.1. 关于研究的风险偏倚评估</title><p>首先，根据修改后的Jadad评分方法可将纳入的文献进行质量评价，其中1~3分视为低质量文献，4~7分视为高质量文献。根据纳入文献的质量测评结果可知：本次试验均为低质量文献，关于分配隐藏、选择性报道及意向性分析均未描述，仅有1篇文献提及了盲法运用。故根据这些方面，不能排除选择性偏倚和报告偏倚。其次，根据偏倚风险百分图和偏倚风险总结图(图1、图2)可知：选择偏倚中随机序列产生的偏倚和失访偏倚属于低风险偏倚，而选择偏倚中分配隐藏产生的偏倚、报告偏倚和其他偏倚不确定因素占比多，实施偏倚和测量偏倚中高风险偏倚占比高。经过研究者共同讨论得出实施偏倚和测量偏倚中高风险偏倚占比高主要存在以下两方面原因：1) 由于该项研究需要通过患者及患者家属知情并签署同意书，故大多文献无法做到实施者和参与者双盲，属于客观因素；2) 研究对象均是通过抑郁发作诊断标准参照《中国精神障碍分类与诊断标准》进行筛选而来，且研究数据的报告形式一致，均采用汉密顿抑郁量表(HAMD)来评定抑郁症的抑郁程度，未曾隐藏个别数据。由于以上风险偏倚不会对我们的研究结果产生过于严重的影响，因此不会存在过多的失误，从而导致结论错误。</p></sec><sec id="s8_2"><title>4.2. 分析总结</title><p>抑郁症又称抑郁障碍，以显著而持久的心境低落为主要临床特征，是心境障碍的主要类型。患者常有症状：意志活动减退、思维迟钝、情绪低落、不愿交流、食欲减退等，严重时会诱发患者产生自杀或自残的行为 [<xref ref-type="bibr" rid="hanspub.38725-ref18">18</xref>]。目前，普遍采用的抗抑郁药治疗方式主要是通过药物调节脑内神经递质水平发挥抗抑郁作用，然而，抗抑郁类药物也被报告出现某些副作用，如：头痛、恶心、口渴、便秘、食欲减退、腹胀腹泻、困倦乏力、记忆力下降、视物模糊、肝功能轻度异常等 [<xref ref-type="bibr" rid="hanspub.38725-ref19">19</xref>]。</p><p>因此，现代临床上可以考虑采用以越鞠丸为基础方治疗抑郁症。中医指出抑郁症病因是由于情志所伤或者七情过极，从而引起肝失调达，长时间累积便形成抑郁 [<xref ref-type="bibr" rid="hanspub.38725-ref20">20</xref>]。根据《丹溪心法》卷三记载，越鞠丸为理气剂–行气剂。具有解诸郁之功效。主治六郁。症见胸膈痞闷，克腹胀痛，嗳腐吞酸，恶心呕吐，饮食不消，舌苔腻，脉弦 [<xref ref-type="bibr" rid="hanspub.38725-ref21">21</xref>]。临床常用于慢性胃炎、慢性肠炎、胃及十二指肠、胃神经症、胆囊炎、肋间神经痛及妇女之痛经、月经不调属气郁者 [<xref ref-type="bibr" rid="hanspub.38725-ref19">19</xref>]。越鞠丸成分：香附、川芎、苍术、神曲、栀子各等分 [<xref ref-type="bibr" rid="hanspub.38725-ref21">21</xref>] (各10 g)。其中，苍术升阳散郁，能开脾气之郁；川芎引清扬之气而止痛，养新生之血以调经，达风木之抑郁，苍术、川芎相伍调肝脾，为越鞠丸中要药 [<xref ref-type="bibr" rid="hanspub.38725-ref22">22</xref>]。越鞠丸治疗抑郁症药理机制：增加脑内5-羟色胺、去甲肾上腺素的含量，降低血浆皮质醇含量，增加海马脑源性神经营养因子(Brain-derived neurotrophic factor, BDNF)的表达有关 [<xref ref-type="bibr" rid="hanspub.38725-ref21">21</xref>]。</p><p>本文共纳入22篇文献，其中，Meta分析用到13篇。而根据Meta分析结果显示：以越鞠丸为基础方治疗各种抑郁症(原发性抑郁症、脑卒中后抑郁症)均具有显著效果，并且以越鞠丸为基础方治疗各种抑郁症相较于传统西药治疗各种抑郁症所出现的不良反应情况更少。故以越鞠丸为基础方治疗各种抑郁症较传统西药治疗各种抑郁症更具优越性，尤其是在治疗原发性抑郁和脑卒中后抑郁上。此外，经研究所采纳的文献大致可见越鞠丸治疗抑郁症各药材在实际治疗中用量在6~15 g之间。根据病症表现加以其他药材一同治疗。</p><p>在此期待上述结果能够有更合理的实验设计、更多样本量以及多中心的随机双盲对照试验研究来进行更细致的说明，并且对分配隐藏、选择性报道相对更高质量的文献进行集中分析，以期为以越鞠丸为基础方治疗各种抑郁症较传统西药治疗优越性这一研究提供更加可靠的数据基础和实验依据。</p></sec></sec><sec id="s9"><title>基金项目</title><p>成都中医药大学杏林学者学科人才科研提升计划(ZRQN2020001)；四川省青年科技创新团队项目(19CXTD0055)。</p></sec><sec id="s10"><title>文章引用</title><p>付 裕,王冬梅,木本荣,国锦琳. 越鞠丸治疗抑郁症较传统西药治疗优越性Meta分析Meta-Analysis on the Superiority of Yueju Pill over Traditional Western Medicine in Treating Depression[J]. 药物资讯, 2020, 09(06): 243-252. https://doi.org/10.12677/PI.2020.96036</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38725-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">王莲芳, 段金凤. 抑郁症病人精神痛苦体验与抑郁症状的相关研究[J]. 全科护理, 2020, 18(4): 483-485.</mixed-citation></ref><ref id="hanspub.38725-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">李焕德, 李革晖. 抗抑郁新药及抑郁症药物治疗的进展[J]. 国外医学. 精神病学分册, 1996(2): 76-81.</mixed-citation></ref><ref id="hanspub.38725-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">汪向东. 心理卫生评定量表手册[M]. 增订版. 北京: 中国心理卫生出版社, 1999: 220-223.</mixed-citation></ref><ref id="hanspub.38725-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">马捷, 刘莹, 钟来平, 张陈平, 张志愿. Jadad量表与Cochrane偏倚风险评估工具在随机对照试验质量评价中的应用与比较[J]. 中国口腔颌面外科杂志, 2012, 10(5): 417-422.</mixed-citation></ref><ref id="hanspub.38725-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">潘洪峰, 董湘玉, 刘瑶, 等. 越鞠保和丸治疗轻中度抑郁症的临床疗效观察[J]. 时珍国医国药, 2008, 19(4): 887-889.</mixed-citation></ref><ref id="hanspub.38725-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">李蓉. 越鞠丸加味治疗抑郁症36例[J]. 河南中医, 2014, 34(5): 974-975.</mixed-citation></ref><ref id="hanspub.38725-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李仲平, 王陶冶, 熊爱莲, 兰润林. 越鞠升降汤治疗轻中度抑郁症36例[J]. 辽宁中医杂志, 2010, 37(8): 1522-1523.</mixed-citation></ref><ref id="hanspub.38725-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王少华. 越鞠丸治疗郁证临床观察[J]. 湖北中医杂志, 2001(1): 35.</mixed-citation></ref><ref id="hanspub.38725-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张煜萱, 崔博, 邹之璐, 任荔, 陈刚. 越鞠丸治疗气郁体质抑郁症患者及改善血清BDNF水平的临床对照研究[J]. 辽宁中医杂志, 2018, 45(5): 960-963.</mixed-citation></ref><ref id="hanspub.38725-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">叶实现. 越鞠丸加味治疗焦虑抑郁障碍31例观察[J]. 实用中医药杂志, 2006(10): 611.</mixed-citation></ref><ref id="hanspub.38725-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">成金汉, 邓金强. 越鞠丸治疗中风后抑郁32例[J]. 临床医药实践, 2009, 18(33): 867.</mixed-citation></ref><ref id="hanspub.38725-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李淑芬. 加味越鞠丸治疗中风后抑郁46例[J]. 湖南中医杂志, 2011, 27(3): 85-86.</mixed-citation></ref><ref id="hanspub.38725-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">孙占卫. 越鞠丸治疗中风后抑郁随机平行对照研究[J]. 实用中医内科杂志, 2014, 28(2): 42-44.</mixed-citation></ref><ref id="hanspub.38725-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">王琪, 赵建军. 疏肝解郁法为主治疗脑卒中后抑郁90例临床观察[J]. 长春中医药大学学报, 2007(2): 50-51.</mixed-citation></ref><ref id="hanspub.38725-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘斯尧, 林彬, 金彩君, 奚郑铮, 丁慧敏. 柴胡越鞠丸治疗脑卒中后抑郁的临床疗效观察[J]. 中国中医药科技, 2014, 21(5): 564-565.</mixed-citation></ref><ref id="hanspub.38725-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">李宝玲, 王进生. 越鞠汤治疗缺血性中风后抑郁症临床观察[J]. 山西中医, 2003, 19(1): 11-12.</mixed-citation></ref><ref id="hanspub.38725-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">李建国, 郭刘峰, 张建宾. 越鞠丸预防脑卒中后抑郁的临床观察[J]. 陕西中医, 2009, 30(6): 678-679.</mixed-citation></ref><ref id="hanspub.38725-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">黄生辉, 陈林庆, 杜国亮. 抑郁症的中西药治疗概述[J]. 河南中医学院学报, 2008(5): 99-101.</mixed-citation></ref><ref id="hanspub.38725-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">马小斯. 抑郁症研究进展[J]. 社会科学前沿, 2020, 9(2): 140-146.</mixed-citation></ref><ref id="hanspub.38725-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">徐肖超, 徐清照. 中医对抑郁症临床治疗的研究[J]. 浙江临床医学, 2020, 22(6): 803-804.</mixed-citation></ref><ref id="hanspub.38725-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">吕小琴, 刘清泉. “越鞠丸, 解诸郁”详解[J]. 环球中医药, 2018, 11(5): 729-731.</mixed-citation></ref><ref id="hanspub.38725-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">张一鸣, 杨勇, 常文杰, 等. 探析越鞠丸之肝脾同调[J]. 中国中医基础医学杂志, 2020, 26(3): 378-380.</mixed-citation></ref></ref-list></back></article>